Velan (VLN) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
19 Jan, 2026Executive summary
Bookings rose to $116.6 million, up 63% year-over-year, and sales increased 22.8% to $98.7 million, driven by strong demand in nuclear power, defense, and oil & gas sectors.
Net income improved to $0.1 million from a $2.1 million loss last year; cash flow from operations was $10.1 million for the quarter and $15 million for the first half.
Achieved highest order backlog in three years at $548.1 million, with $395.9 million deliverable within 12 months.
Secured major nuclear sector agreements, including a main services agreement with GEH SMR Technologies and a CAD 50 million, 10-year alliance with Bruce Power.
Diversified product portfolio and global reach contributed to growth, with strong sectoral contributions.
Financial highlights
Q2 sales totaled $98.7 million, up 22.8% year-over-year, with growth from Italy, France, and North America; included a $5.2 million non-recurring revenue gain from a canceled contract.
Gross profit was $26.7 million (27% margin), up from $23.4 million last year; adjusted gross margin excluding non-recurring gain was 28.5%.
EBITDA reached $5.1 million, up from $3.0 million last year; adjusted EBITDA was $5.1 million, up from $3.3 million.
Cash and equivalents stood at $44.5 million, with short-term investments of $4.8 million and long-term debt of $22.6 million as of August 31, 2024.
Book-to-bill ratio was 1.18 for the quarter and 1.29 for the first six months.
Outlook and guidance
Maintains sales growth outlook for the fiscal year, supported by record backlog and strong bookings.
Expects continued momentum in the second half, with $395.9 million of orders deliverable within 12 months.
Gross margin expected to benefit from contract execution and fixed capacity, with admin costs stabilizing around current levels.
Latest events from Velan
- Bookings and backlog improved, supporting growth and cash flow focus for 2025.VLN
AGM 20243 Feb 2026 - Q1 sales up 14.5%, gross margin 30.7%, backlog $528.3M, and major nuclear deal signed.VLN
Q1 20253 Feb 2026 - Strong backlog, major asset sale, and ownership transition marked Q3 2026.VLN
Q3 202615 Jan 2026 - Q3 saw 18.1% sales growth, margin gains, and risk reduction from major divestitures.VLN
Q3 202510 Jan 2026 - Shareholders approved the $201.1 million sale of French subsidiaries to Framatome.VLN
EGM 202526 Dec 2025 - Sales and margins surged, with divestitures and a special dividend boosting future prospects.VLN
Q4 202524 Nov 2025 - 18.6% sales growth, margin gains, and record cash drive a higher dividend and strong outlook.VLN
Q1 202616 Nov 2025 - Strong growth, risk reduction, and strategic expansion defined the year, with all motions approved.VLN
AGM 202516 Nov 2025 - Q2 sales fell 13%, but backlog and liquidity rose, supporting growth in key sectors.VLN
Q2 202612 Oct 2025